Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
International Journal of Cancer|March 7, 2014
Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health InitiativeTheodore M Brasky, Jingmin Liu, Emily White, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2026
Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-guided and Risk-Adaptive Chemoradiation for Unresectable NSCLCJing Zeng, Sunan Cui, Daniel S Hippe, et al.
The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
Cancer Medicine|March 29, 2022
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patientsCameron Chalker, Jenna M Voutsinas, Qian Vicky Wu, et al.
Journal of Palliative Medicine|December 1, 2021
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint InhibitorsCameron Chalker, Rafael Santana-Davila, Jenna M Voutsinas, et al.
Nature Microbiology|April 30, 2026
Streptomyces produce a diphtheria toxin-like exotoxin that targets insectsYing Xu, Reed M Stubbendieck, Raghuvir Viswanatha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and BiomarkersSolange Peters, Rolf Stahel, Lukas Bubendorf, et al.
Advances in Radiation Oncology|April 7, 2022
Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung CancerStephen R Bowen, Daniel S Hippe, Hannah M Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and ImmunotherapyConor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
Medrxiv : the Preprint Server for Health Sciences|March 31, 2025
Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancerNatalie J Miller, Christina S Baik, Joel W Neal, et al.
Pageof 12